

APBMT Registry "LMD"

Disease classification sheet

ATL

AML

ALL

Other Acute Leukemias

	ACUTE LEUKEMIAS
Unique Patient Number or Code:	
Date of this HSCT: (ууу	ry - mm - dd)
Classification (Check ONLY ONE):	
AML with recurrent genetic abnormalities	Acute Lymphoblastic Leukemia (ALL) Other Acute Leukemias
□ AML with t(8;21)(q22;q22), (AML1/ETO) □ AML with abnormal bone marrow eosinophils and inv(16)(p13;q22) or t(16;16)(p13;q22) CBFβ/MYH11) □ AML with t(15;17)(q22;q12), (PML/RARα) and variants (FAB M3) □ AML with 11q23, (MLL) abnormalities □ AML with multilineage dysplasia (w/o MDS or MPS/MDS antecedents)	□ Precursor B-cell ALL □ t(9;22)(q34;q11); BCR/ABL □ t(v;11q23); MLL rearranged □ t(1;19)(q23;p13) E2A/PBX1 □ t(12;21)(p12;q22) ETV/CBF-alpha □ Precursor T-cell ALL □ ALL not otherwise specified
,	Adult T-cell lympoma/leukemia(HTLV1+)
AML not otherwise categorised	
AML, minimally differentiated (FAB M0) AML without maturation (FAB M1) AML with maturation (FAB M2) Acute myelomonocytic leukemia (FAB M4) Acute monoblastic/acute monocytic leukemia (FAB M5) Acute erythroid leukemia (erythroid/myeloid and pure erythacute megakaryoblastic leukemia (FAB M7) Acute basophilic leukemia (FAB M7) Acute panmyelosis with myelofibrosis Myeloid sarcoma AML not otherwise specified Transformed from MDS → Complete MDS section on Disception Except ATL Yes: Disease related to prior exposure to therapeutic drugen No Unknown	sease Classification Sheet MDS. Do not complete the remainder of AML.
Status at HSCT:	
STATUS	
□ Primary induction failure □ Complete haematological remission (CR) □ Relapse □ Never treated	
NUMBER (Complete only for CR or relapse) 1st 2nd 3rd or higher	
FOR COMPLETE REMISSION ONLY, TYPE OF REMISSION	
No Yes Not e Cytogenetic Molecular	evaluated Unknown

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	1000/	mm	dd



APBMT Registry "LMD"

Disease classification sheet



CHRO	NIC MYELC	GENO	US LEUKEMIA	(CML) Note: CMI
Unique Patient Number or Code:				
Date of this HSCT:		(yy	yy - mm - dd)	
Classification:				
At least one investigation must be po	sitive			
Translocation (9;22)	□ Absent		Present	□ Not evaluated
bcr-abl	□ Absent		Present	□ Not evaluated
Status at HSCT:				
PHASE				
□ Chronic phase (CP)				
□ Accelerated phase				
☐ Blast crisis				
NUMBER (CP only)				
□ 1st				
□ 2nd				
☐ 3rd or higher				
FOR CHRONIC PHASE ONLY Pre	esence and typ	e of CR	(Check all that ap	ply)
Haematological	□ Yes	\square No	□ Not evaluate	ed 🗆 Unknown
Cytogenetic (t(9;22))	□ Yes	□ No	□ Not evaluate	ed 🗆 Unknown
Molecular (bcr-abl)	□ Yes	□ No	□ Not evaluate	ed 🗆 Unknown

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd





APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd



CLL /PLL / Other

OTHER LEUKEMIAS
Unique Patient Number or Code: Date of this HSCT: (yyyy - mm - dd)
Classification:
Chronic lymphocytic leukemia (CLL) Prolymphocytic Leukemia (PLL) PLL, B-cell PLL, T-cell Hairy Cell Leukemia Other leukemia, specify: Status at HSCT
☐ Stable disease/No response
□ Complete remission (CR) □ Partial remission (PR)
□ nodular Partial remission (nPR)
□ Relapse
□ Progression
□ Never treated

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		-
	, ,	уууу	mm	dd





Unique Patient Number or Code:		
Date of this HSCT:	(yyyy - mm - dd)	
Combined My	velodysplastic/Myeloproliferative Syndrom	e (MD/MPS)
Classification at HSCT:		
 □ Chronic myelomonocytic leukaemia (CMMo □ Juvenile myelomonocytic leukaemia (JCMM □ Atypical CML ((t(9;22) negative and bcr/abl □ Transformed to AML: Date of transformation 	/IOL, JMML, JCML, JCMML)	
Secondary origin: (other than transformed to AML)	 ☐ Yes: Disease related to prior exposure to there ☐ No ☐ Unknown 	apeutic drugs or radiation
Status at HSCT :		
MDS or CMML (including Transformed to AM	L) / Atypical CML	JMML
Treated with chemotherapy: Primary refractory phase (no change) Complete remission (CR) Improvement but no CR Relapse (after CR) Progression/worse Untreated (Supportive care or treatment w	NUMBER (Complete for CR or relapse) ☐ 1st ☐ 2nd ☐ 3rd or higher //ithout chemotherapy)	□ Stable disease (SD) □ Complete response (CR) □ Minimal response (MR) □ Partial response (PR) □ Progression (PD)
	YELOPROLIFERATIVE SYNDROMES (MPS))
Classification at HSCT:		
 □ Chronic idiopathic myelofibrosis (primary m □ Polycythemia vera □ Essential or primary thrombocythemia □ Hyper eosinophilic syndrome (HES) □ Chronic eosinophilic leukemia (CEL) □ Chronic neutrophilic leukemia □ Stem cell leukemia-Lymphoma syndrome (8 □ Secondary myelofibrosis: □ Transformed to AML: Date of transformation □ MPS not otherwise specified □ Other, specify: Secondary origin: (other than transformed to AML) 	8p11 syndrome)	rapeutic drugs or radiation
Status at HSCT:		
☐ Treated with chemotherapy:		
☐ Primary refractory phase (no change)	NUMBER (Complete for CR	₹ or relapse)
□ Complete remission (CR)	□ 1st	
☐ Improvement but no CR	□ 2nd	
□ Relapse (after CR)	☐ 3rd or higher	
□ Progression/worse		
☐ Untreated (Supportive care or treatment without	out chemotherapy)	

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd





Hodgkin



	LYMPHO	DMAS	
Unique Patient Number or Code:			
	(yyyy - mm - dd)		
Classification:			
Non-Hodgkin's lymphoma (NHL):			
B-cell Neoplasms		T-cell & NK-cell Neoplasms	
☐ Follicular lymphoma		□ Angioimmunoblastic (AILD)	
☐ Grade I ☐ Grade II ☐ Grad	e III 🗆 Unknown	□ Peripheral T-cell lymphoma (all variants)	
☐ Mantle cell lymphoma		☐ Anaplastic large-cell, T/null cell, primary cutaneous	
☐ Extranodal marginal zone of MAL	T type	☐ Anaplastic large-cell, T/null cell, primary systemic	
☐ Diffuse large B-cell lymphoma (If I	known indicate subtype)	□ Extranodal NK/T-cell lymphoma, nasal type	
☐ Intravascular large cell lymph	oma	☐ Enteropathy-type T-cell lymphoma	
☐ Mediastinal large cell lymphor	ma	☐ Hepatosplenic gamma-delta T-cell lymphoma	
☐ Primary effusion large cell lyn	nphoma	☐ Subcutaneous panniculitis-like T-cell lymphoma	
☐ Burkitt's lymphoma/Burkitt cell leu	kemia (ALL L3)	□ Adu <mark>削除</mark>	
☐ High grade B-cell lymphoma,	Burkitt-like (provisional entity)	☐ Aggressive NK-cell leukemia	
☐ Lymphoplasmacytic lymphoma		☐ Large T-cell granular lymphocytic leukemia	
☐ Waldenstrom macroglobulinaemia	1	☐ Mycosis fungoides	
☐ Splenic marginal zone B-cell lymp	homa	□ Sezary syndrome	
☐ Nodal marginal zone B-cell lymph	oma	☐ Other T/NK-cell, specify:	
□ Primary CNS lymphoma			
☐ Other B-cell, specify:			
Hodgkin:			
□Nodular lymphocyte predominant	□Lymphocyte rich	□Nodular sclerosis □Mixed cellularity	
□Lymphoma depleted	□Other, specify:		
Adult T-cell lymphoma/leu	ukemia(HTLV1+) <u>Complet</u> e	e ATL section on Disease Classification Sheet AM	L/ALL
OAL/ATL. Do not complete the	nis sheet.		
Status at HSCT:			
STATUS	NUMBER	SENSITIVITY TO CHEMOTHERAPY VSENSIT	
□ Never treated	(Complete only for CR, PR>1 or		
□ Primary refractory	□ 1st	□ Sensitive	
Complete remission (CR)	□ 2nd	□ Resistant	
☐ Confirmed ☐ Unconfirmed (CRU	*) □ 3rd or higher	□ Untreated	
☐ 1st Partial response (PR1)	. A)	□ Unknown	
□ Partial response>1 <i>(never in CR)</i> (PR	(21)		
□ Relapse			
□ Progression	malata anno anno 1900 e e este te de		
"CRU – cor	ripiete response with persistent sca	an abnormalities of unknown significance	

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd



PCD(MM)

nique Patient Number or Code:	
ate of this HSCT:	(yyyy - mm - dd)
Classification:	
IG CHAIN TYPE	
☐ Multiple myeloma IgG	
☐ Multiple myeloma IgA	
☐ Multiple myeloma IgD	
☐ Multiple myeloma IgE	
☐ Multiple myeloma IgM (not Waldenstrom)	
☐ Multiple myeloma- light chain only	
☐ Multiple myeloma-non-secretory	
LIGHT CHAIN TYPE	
□ Kappa	
□ Lambda	
OTHER	
□ Plasma cell leukemia	
□ Solitary plasmacytoma	
□ Primary amyloidosis	
☐ Other, specify:	
Status at HSCT:	
□ Never treated	
☐ Complete remission (CR)	
□ Partial remission (PR)	
☐ Minimal response (MR)	
☐ Relapse from CR (untreated)	
□ Progression	
□ No change / stable disease	
NUMBER (Complete for CR, PR or relapse):	
□ 1st	
□ 2nd	
☐ 3rd or higher	

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd



APBMT Registry "LMD"

Disease classification sheet

SAA

BM aplasia-other

ANEMIA	
Unique Patient Number or Code:	
Date of this HSCT: (yyyy - mm - dd)	
Classification: Acquired Severe Aplastic Anemia (SAA), not otherwise specified Acquired SAA, secondary to hepatitis Acquired SAA, secondary to toxin/other drug Amegakaryocytosis, acquired (not congenital) Acquired Pure Red Cell Aplasia (PRCA) (not congenital) Other acquired cytopenic syndrome, specify: Paroxysmal nocturnal hemoglobinuria (PNH)	
Congenital: Fanconi anemia Diamond-Blackfan anemia (congenital PRCA) Schwachman-Diamond Other congenital anemia, specify:	

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd



Hemoglobinopathy

HEMOGLOBINOPATHY				
Unique Patient Number or Code:				
Date of this HSCT: (yyyy - mm - dd				
Classification: Thalassemia Sickle cell disease Other hemoglobinopathy, specify:				

NPBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, , ,	уууу	mm	dd



Solid tumor

Solid Tumor
Unique Patient Number or Code:
Date of this HSCT: (yyyy - mm - dd)
Classification: Bone sarcoma (excluding Ewing sarcoma/PNET) Colorectal Ewing sarcoma/PNET, extra-skeletal Ewing sarcoma/PNET, skeletal Gern cell tumor, extragonadal only Hepatobiliary Lung cancer, non-small cell Lung cancer, small cell Medulloblastoma Melanoma Breast Neuroblastoma Ovarian Pancreas Prostate Renal cell Retinoblastoma Rhabdomyosarcoma Soft tissue sarcoma Testicular Thymoma Wilms tumor Other, specify
Status at HSCT: Adjuvant Never treated (upfront) Stable disease/no response Complete remission (CR) Confirmed Unconfirmed (CRU*) 1st Partial response (PR1) Relapse Progressive disease (PD) *CRU – complete response with persistent scan abnormalities of unknown significance
NUMBER (complete only for CR or relapse): ☐ 1st ☐ 2nd ☐ 3rd or higher
SENSITIVITY TO CHEMOTHERAPY (Complete only for relapse) Sensitive Resistant Untreated



Other	
Unique Patient Number or Code:	
Date of this HSCT: (yyyy - mm	- dd)
PRIMARY IM	MUNE DEFICIENCIES
Classification:	
□ Absence of T and B cells SCID □ Absence of T, normal B cell SCID □ ADA deficiency severe combined immune deficiency (SCID) □ Ataxia telangiectasia □ Bare lymphocyte syndrome □ Cartilage hair hypoplasia □ CD 40 Ligand deficiency □ Chediak-Higashi syndrome □ Chronic granulomatous disease □ Common variable immunodeficiency □ DiGeorge anomaly	□ Kostmann syndrome-congenital neutropenia □ Leukocyte adhesion deficiencies □ Neutrophil actin deficiency □ Omenn syndrome □ Reticular dysgenesis □ SCID other, specify: □ SCID, unspecified □ Wiskott Aldrich syndrome □ X-linked lymphoproliferative syndrome □ Other, specify: □ Immune deficiencies, not otherwise specified
INHERITED DISC	PRDERS OF METABOLISM
Classification:	RDERS OF WIETABOLISM
□ Adrenoleukodystrophy □ Aspartyl glucosaminuria □ B-glucuronidase deficiency (VII) □ Fucosidosis □ Gaucher disease □ Glucose storage disease □ Hunter syndrome (II) □ Hurler syndrome (IH) □ I-cell disease □ Krabbe disease (globoid leukodystrophy) □ Lesch-Nyhan (HGPRT deficiency) □ Mannosidosis □ Maroteaux-Lamy (VI)	Metachromatic leukodystrophy Morquio (IV) Mucolipidoses, unspecified Mucopolysaccharidosis (V) Mucopolysaccharidosis, unspecified Niemann-Pick disease Neuronal ceriod − lipofuscinosis (Batten disease) Polysaccharide hydrolase abnormalities, unspecified Sanfilippo (III) Scheie syndrome (IS) Wolman disease Other, specify: Inherited disorders of metabolism, not otherwise specified
Classification:	
□ Glanzmann thrombasthenia □ Congenital amegakaryocytosis / congenital thrombocytopenia □ Other inherited platelet abnormalities, specify: □ Osteopetrosis (malignant infantile osteopetrosis) □ Other osteoclast defects, specify:	
HISTIOC	YTIC DISORDERS
Classification: □ Histiocytic disorders, not otherwise specified □ Langerhans Cell Histiocytosis (Histiocytosis-X) □ Malignant histiocytosis	□ Familial erythro/hemophagocytic lymphohistiocytosis (FELH) □ Hemophagocytosis (reactive or viral associated) □ Other, specify:

APBMT Center# :	Unique Patient Number (UPN):	HSCT Date		
	, ,	уууу	mm	dd

	AUTOIMMUNE DISC	RDERS		
	Involved Organs/Clinical Problem at HSCT	<u>Reason f</u>	for HSCT	
CONNECTIVE TISSUE DISE	EASE			
☐ Systemic sclerosis (SS)				
	diffuse cutaneous limited cutaneous lung parenchyma pulmonary hypertension systemic hypertension renal (biopsy type:) oesophagus other GI tract Raynaud CREST other, specify:	Presence No Yes	Indication for	
Antibodies studied	□ No □ Yes: Scl 70 positive □ Normal/Negative □ Unknown		ated/Positive ated/Positive	☐ Not evaluated ☐ Not evaluated
☐ Systemic lupus erythemato	osus			
(SLE)	renal (biopsy type:) CNS (type :) PNS (type :) lung serositis arthritis skin (type:) hematological (type:) vasculitis (type:)	Presence No Yes	Indication for	HSCT
Antibodies studied	□ No □ Yes: ds DNA □ Normal/Negative Complement □ Normal/Negative Other, specify □ unknown	□ Eleva	ated/Positive ated/Positive	☐ Not evaluated ☐ Not evaluated
□ Polymyositis- dermatomyos	iitis			
	□ proximal weakness □ generalized weakness (including bulbar) □ pulmonary fibrosis □ vasculitis (type:) □ other, specify:	Presence No Yes No Yes No Yes No Yes No Yes No Yes	Indication fo	Yes Yes Yes Yes
Manifestation with:	□ typical biopsy □ typical EMG □ typical rash (DM) □ CPK elevated □ malignancy (type:)			
□ Sjögren syndrome	□ SICCA □ exocrine gland swelling □ other organ lymphocytic infiltration □ lymphoma, paraproteinemia □ other, specify:	Presence □ No □ Yes	Indication for No No No	Yes Yes Yes Yes

sification In:	volved Organs/Clinical Problem at HSC* ASE (CONT.)	Reason for HS	<u>CT</u>
ntiphospholipid syndrome			
	□ thrombosis (type:) □ CNS (type:) □ abortion □ skin (livido, vasculitis) □ hematological (type:) □ other, specify:	Presence No Yes No Yes	Indication for HSCT No Yes No Yes
Antibodies studied	☐ Yes: Anticardiolipin lgG Anticardiolipin lgM	□ Normal/Negative □ Elevate □ Normal/Negative □ Elevate	
ther type of connective tis	sue disease, specify:	-	
CULITIS /egener granulomatosis			
	upper respiratory tract pulmonary renal (biopsy type:) skin other, specify:	Presence No Yes No Yes No Yes No Yes No Yes No Yes	Indication for HSCT No Yes
Antibodies studied	□ No □ Yes: c-ANCA □ unknown	□ Negative □ Positive	□ Not evaluated
lassical polyarteritis nodos □ Classical □ Microscopic	sa		
	renal (type:) mononeuritis multiplex pulmonary hemorrhage skin GI tract other, specify:	Presence	Indication for HSCT □ No □ Yes
Antibodies studied	□ No □ Yes: p-ANCA c-ANCA Hepatitis serology □ unknown	□ Negative □ Positive □ Positive □ Positive □ Positive	□ Not evaluated□ Not evaluated□ Not evaluated

_____ HSCT Date___

_____ - _

mm dd

APBMT Center# : _____ Unique Patient Number (UPN):___

ARTHRITIS					
☐ Rheumatoid arthritis					
	destructive arthritis necrotising vasculitis eye (type: pulmonary extra articular (specify: other, specify:)	Presence No Yes	Indication for HSCT No Yes No Yes No Yes No Yes No Yes No Yes No Yes	
☐ Psoriatic arthritis/psorias	sis				
	□ destructive arthritis □ psoriasis □ other, specify:		Presence No Yes No Yes No Yes	Indication for HSCT No Yes No Yes No Yes	
	tis (JIA), systemic (Stills diseas				
☐ Juvenile idiopathic arthri	tis (JIA), articular:	Onset	□ Oligoarticular □ Polyarticular		
☐ Juvenile idiopathic arthri	tis: other, specify:		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
☐ Other arthritis:					
□ Multiple sclerosis	 □ primary progressive □ secondary progressive □ relapsing/remitting □ other: 	_			
OTHER NEUROLOGICAL	. AUTOIMMUNE DISEASE				
☐ Myasthenia gravis☐ Other autoimmune neuro	ological disorder, specify:				
HEMATOLOGICAL AUTO	DIMMUNE DISEASES				
 □ Idiopathic thrombocytope □ Hemolytic anemia □ Evan syndrome □ other autoimmune cytope 	enic purpura (ITP) enia, specify:				
BOWEL DISEASE Crohn's disease Ulcerative colitis Other autoimmune bowe	el disease, specify:				
☐ Diabetes Mellitus (type I	OGICAL AUTOIMMUNE DISEA) I autoimmune disorder, specify				

_____ HSCT Date____

_____- - _

mm dd

APBMT Center# : _____ Unique Patient Number (UPN):____